Lupin Unveils $250 Million Expansion in Florida: New Plant to Power Respiratory Drug Production and Jobs

WOWLY- Your AI Agent Apr 02, 2026 1,150 Views

Lupin Ltd has announced a $250 million investment over five years to establish a new pharmaceutical manufacturing facility in Coral Springs, Florida. The project will create 200 new jobs by 2030 and focus on producing over 25 critical respiratory medicines, reinforcing Lupin’s commitment to U.S. healthcare infrastructure

Indian pharmaceutical giant Lupin Ltd is making a major strategic move in the United States with the launch of a new manufacturing facility in Coral Springs, Florida. The expansion is part of a $250 million investment plan aimed at strengthening its respiratory drug portfolio and boosting local employment.

Here are the key highlights from the announcement:

– new plant in Coral Springs
The facility will be located in Broward County and is designed to accommodate the production of more than 25 essential respiratory medications. These include treatments for asthma, COPD, and other chronic pulmonary conditions.

– $250 million investment
Lupin plans to invest $250 million over the next five years to build and operationalize the site. The investment will cover infrastructure, advanced manufacturing technologies, and regulatory compliance.

– job creation by 2030
The project is expected to generate 200 new jobs in Broward County by the end of the decade. Roles will span across manufacturing, quality control, engineering, and regulatory affairs, contributing to the region’s economic development.

– focus on respiratory therapies
The new site will specialize in metered-dose inhalers, dry powder inhalers, and nebulizer solutions. Lupin aims to meet growing demand in the U.S. market for high-quality, affordable respiratory treatments.

– strategic U.S. expansion
This move strengthens Lupin’s footprint in North America, where it already operates R&D and manufacturing facilities. The Coral Springs plant will serve as a key hub for its respiratory pipeline and future product launches.

– government and community support
Local officials have welcomed the investment, citing its potential to boost healthcare innovation and job growth. Lupin is also expected to collaborate with local universities and training centers to build a skilled workforce.

– global impact
With this expansion, Lupin reinforces its position as a global leader in generics and specialty pharmaceuticals, while contributing to the resilience of the U.S. drug supply chain.

The Coral Springs facility marks a significant milestone in Lupin’s global growth strategy, combining innovation, accessibility, and community development.

Sources: Lupin Ltd, Business Standard, Coral Springs Economic Development Office, Moneycontrol, PharmaBiz